Bergapten, another active constituent, could enhance p53-mediated apoptotic cascades and suppress AKT phosphorylation, hence decreasing CRC cell viability and triggering cell cycle arrest (Lin et al., 2019). The gene discussed is TP53; the disease is colorectal carcinoma.